硫酸羟氯喹(Hydroxychloroquine Sulfate) - 在研适应症：盘状红斑狼疮，疟疾，皮肤红斑狼疮_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(±)-hydroxychloroquine、2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol、2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol

+ [20]

靶点-

作用机制-

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病+ [5]

在研适应症

盘状红斑狼疮疟疾皮肤红斑狼疮+ [10]

非在研适应症

晚期乳腺癌晚期癌症晚期恶性实体瘤+ [8]

原研机构

Sanofi

在研机构

上海中西三维药业有限公司

National Cancer Institute

Novitium Pharma LLC初创企业

+ [5]

非在研机构

National Heart, Lung & Blood Institute

SanofiPulmoquine Therapeutics, Inc

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1955-04-18),

急性疟疾类风湿关节炎系统性红斑狼疮

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C18H28ClN3O5S

InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N

CAS号747-36-4

关联

630

项与硫酸羟氯喹相关的临床试验

NCT05842174 / Not yet recruiting临床1/2期

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy

Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.

开始日期2024-07-01

申办/合作机构

VA Office of Research and Development

NCT05689359 / Withdrawn临床2期IIT

Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent

The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.

开始日期2024-06-01

申办/合作机构

University of Arizona

NCT06389201 / Not yet recruitingN/AIIT

Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

Dormant cancer cells that survive anti-cancer therapy can lead to cancer recurrence and disseminated metastases that prove fatal in most cases. Recently, specific dormant polyploid giant cancer cells (PGCC) have drawn our attention because of their association with the clinical risk of nasopharyngeal carcinoma (NPC) recurrence, as demonstrated by previous clinical data. In study, we report the biological properties of PGCC, and reveal that autophagy is a critical mechanism of PGCC induction. Moreover, pharmacological inhibition of autophagy greatly impaired PGCC formation, significantly suppressing metastasis and improving survival in a mouse model. Mechanistically, chemotherapeutic drugs partly damaged mitochondria, and activated autophagy to promote PGCC formation. High numbers of PGCCs correlated with shorter recurrence time and worse survival outcomes in NPC patients. Collectively, these findings suggest a therapeutic approach of targeting dormant PGCCs in cancer.
Pretreatment with an autophagy inhibitor (HCQ) before chemotherapy and radiotherapy could prevent formation of therapy-induced dormant polyploid giant cancer cells, thereby reducing recurrence and metastasis of nasopharyngeal carcinoma.

开始日期2024-05-01

申办/合作机构

南通大学附属医院

100 项与硫酸羟氯喹相关的临床结果

登录后查看更多信息

100 项与硫酸羟氯喹相关的转化医学

登录后查看更多信息

100 项与硫酸羟氯喹相关的专利（医药）

登录后查看更多信息

9,081

项与硫酸羟氯喹相关的文献（医药）

2024-07-01·Joint Bone Spine

Hand osteoarthritis: A fresh look

Article

作者: Richette, Pascal ; Latourte, Augustin

Hand osteoarthritis (OA) has been the subject of numerous publications in recent years, particularly in the fields of imaging and therapeutics. The imaging studies revealed a good correlation between the presence of synovitis and/or subchondral edema and arthritic joint pain. Several randomized controlled trials (RCTs) have assessed the efficacy of biologics and conventional DMARDs in patients with symptomatic hand OA. No less than six RCTs have evaluated the symptomatic and, in some cases, structural efficacy of anti-IL-1, anti-TNF or anti-IL-6 drugs. Overall, the results of these trials were disappointing - none of them demonstrated superiority over placebo. There were also two negative trials with hydroxychloroquine. In the end, the only trial that was positive evaluated 10mg oral prednisone versus placebo for 6 weeks in patients with flares of hand OA and synovitis visible on ultrasound. While that trial confirms the role of inflammation in hand OA, it should obviously not encourage the long-term use of corticosteroids as a symptomatic treatment.

2024-06-01·Journal of Translational Autoimmunity

Effect of traditional therapeutics on prevalence and clinical outcomes of coronavirus disease 2019 in Chinese patients with autoimmune diseases

Article

作者: Xu, Xue ; Sun, Lingyun ; Wang, Dandan ; Huang, Saisai ; Liang, Jun ; Ma, Xiaolei ; Zhao, Zhiling ; Cao, Juan ; Du, Mengru

The impact of the Coronavirus disease 2019 (COVID-19) pandemic on autoimmune diseases (AID) patients has been an important focus. This study was undertaken to characterize the incidence, clinical manifestations and hospitalization among AID affected by COVID-19 and to analyze the association between immunomodulatory medication and these outcomes. Clinical, demographic, maintenance treatment, symptoms and disease course data and outcomes of AID patients with COVID-19 infection were assessed via an online survey tool and printed copy from 1 January till February 28, 2023. A total of 432 patients with AID were enrolled in the study. The results showed the most common conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was hydroxychloroquine (HCQ). The usage of csDMARDs didn't increase the risk of COVID-19 infection. Patients who warranted hospitalization were significantly older. ILD was associated with higher hospitalization rate. No csDMARDs other than calcineurin inhibitor (CNI) was associated with increased risk of hospitalization. HCQ intake was associated with cough. Compared with no glucocorticoids (GCs) group, high doses of GCs were accompanied with higher proportion of gastrointestinal symptoms and tachycardia, lower proportion of sore throat and ageusia. GCs didn't provoke the COVID-19 infection in patients with AID, but chronic use of oral GCs was significantly more common in those requiring hospitalization, and higher dose of GCs were correlated with higher risk of hospitalization. 97 patients discontinued csDMARDs after infection, which resulted in an elevated risk of hospitalization. Meanwhile, withdrawal of csDMARDs was associated with higher odds of disease flare and lower proportion of remission than maintenance groups. Collectively, our analysis provides the evidence that maintenance treatment of csDMARDs may be more prudent for AID patients during COVID-19 pandemic.

2024-05-01·Current Rheumatology Reviews

Refractory Adult-onset Still’s Disease Treated with a Combination of Methotrexate and Etanercept

作者: Ahmad, Yaser ; El Hasbani, Georges ; Cassetta, Michael

Background::

Adult-onset Still’s disease (AOSD) is a challenging diagnosis because of the variability in clinical presentation and lack of gold-standard diagnostic investigations. Even after diagnosis, the treatment is challenging, especially when the disease is refractory to first-line therapy. Multiple pharmacotherapeutic options exist for refractory AOSD, but treatment failures still occur. Etanercept, a Tumor necrosis factor (TNF)-alpha inhibitor, is one of the options that has been rarely used for refractory AOSD, with various outcomes ranging from no response to complete remission.

Case Presentation::

In this case, we highlight how a previously healthy lady had refractory AOSD to glucocorticoids, methotrexate, and hydroxychloroquine combination therapy. There was no response to interleukin (IL)-1 therapy, which necessitated a switch to a combination of etanercept, low-dose methotrexate, and low-dose glucocorticoids with complete remission for a total of three- -year follow-up.

Conclusion::

The combination of methotrexate and Etanercept can maintain remission in patients with refractory AOSD.

90

项与硫酸羟氯喹相关的新闻（医药）

2024-05-04

·医药观澜

《柳叶刀》：CAR-T治疗自身免疫疾病再获突破

▎药明康德内容团队编辑系统性红斑狼疮（SLE）是一种自身免疫性疾病，治疗不及时，会造成受累脏器的不可逆损害，最终导致患者死亡。根据《2020中国系统性红斑狼疮诊疗指南》数据，中国大陆地区SLE患病率约为30~70万/10万，男女患病比为1：10~12。约50%~78%的SLE患者会发生肾脏受累，称为“狼疮肾炎”。通常SLE被确诊后前5年就会出现狼疮肾炎，其中1/5的患者发病时处于青春期。青少年狼疮肾炎无论是发病率还是死亡率均高于成人。常规疗法（如免疫抑制剂）仅可使60%的青少年狼疮肾炎患者达到完全缓解的目标，且2/3的患者在未达到药物缓解时已出现器官受损。过度活化的B细胞几乎参与了狼疮发病的全过程，因此CD19靶向嵌合抗原受体（CAR）-T细胞是治疗SLE的潜在有力策略。近日，《柳叶刀》（The Lancet）发表了德国埃尔兰根大学Markus Metzler教授团队的通信文章，一位出现狼疮肾炎的青少年患者在使用抗CD19 CAR-T后，病情得到了持续缓解。论文提交出版社时，该患者已恢复正常生活。截图来源：The Lancet该团队报告了一例15岁严重且病情进展迅速的系统性红斑狼疮女性患者，尽管使用了硫酸羟氯喹、硫唑嘌呤、吗替麦考酚酯和贝利尤单抗后，患者肾功能还是在6个月后恶化，出现重度肾炎伴蛋白尿（24小时肌酐值高达10717 mg/g）、镜下血尿。接下来4周，患者肌酐值升高至1.7 mg/dl（正常范围0.41~0.81 mg/dl），伴有高磷血症和肾小管酸中毒，肾脏活检提示为4级狼疮肾炎。改良美国国立卫生研究院（NIH）活动指数为15（最大值为24），改良NIH慢性指数为1（最大值为12）。患者补体水平降低，体内发现多种自身抗体，如抗核抗体、抗双链DNA、抗核小体和抗组蛋白抗体。治疗未能阻止患者肾衰的发生，8.5个月后，患者肌酐水平升高至4.96 mg/dl，患者需要接受血液透析和降压治疗。实验室检查结果显示，系统性红斑狼疮病情活动程度（SLEDAI）评分23分（超过20分已属于非常罕见），病情很是严重。此前，德国风湿免疫学家Georg Schett团队在《新英格兰医学杂志》（NEJM）发表的一项具有里程碑意义的临床研究成果显示，8例系统性红斑狼疮患者在治疗6个月后均达到狼疮低疾病活动状态（LLDAS）标准，并达到系统性红斑狼疮缓解定义（DORIS）缓解，长达29个月的随访显示，狼疮肾炎未再发生。那么，这位患者是否也能从CAR-T细胞疗法中获益呢？我们来看结果：输注CAR-T细胞1周后，血液透析的间隔时间有所延长。输注CAR-T细胞3个月，肌酐水平降低至1.2 mg/L，预估的肾小球滤过率从最低的8 ml/min/173m2增加到24/min/173m2，即属于3b期慢性肾病。降压用药也开始减量。4个月时，患者已顺利返校。6个月时，患者关节炎症状消退，补体因子C3和C4在6周内恢复正常，抗核抗体抗dsDNA和其他自身抗体均消失，患者肾功能显著改善。24 h蛋白尿降低至3400 mg，但末次随访时水平仍有所升高，这提示患者还是出现了一些不可逆的肾小球损伤。血浆白蛋白浓度正常，无水肿；尿液成分分析未发现肾炎体征，无血尿和红细胞管型尿。论文提交出版社时，该患者日常生活已恢复正常。文章表示，这是“首个”靶向CD19的CAR-T疗法在系统性红斑狼疮青少年患者中的应用，从结果来看，CAR-T疗法让疾病快速进展的难治性狼疮肾炎患者实现了持续缓解。相比于此前靶向CD19的CAR-T疗法在成人中的应用，该患者已处于终末期肾病阶段，需要每2~3天接受一次血液透析，尽管如此，CAR-T细胞疗法也仍被证明是安全且有效的。这意味着CAR-T细胞疗法有望让狼疮肾炎患者摆脱药物依赖和血液透析，提高患者预后。据公开资料，目前CAR-T疗法在免疫系统疾病2期正在进行中的临床试验（不包含启动中或已暂停试验）共有13项。点击文末“阅读原文/Read more”，即可访问The Lancet官网阅读完整论文。参考资料：[1] Krickau T, Naumann-Bartsch N, Aigner M, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024 Apr 27;403(10437):1627-1630. doi: 10.1016/S0140-6736(24)00424-0. Epub 2024 Apr 17. PMID: 38642568.本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

细胞疗法免疫疗法临床结果ASH会议

2024-05-03

·药明康德

“首例”患者已恢复正常生活！《柳叶刀》：CAR-T治疗自身免疫疾病再获突破

系统性红斑狼疮（SLE）是一种自身免疫性疾病，治疗不及时，会造成受累脏器的不可逆损害，最终导致患者死亡。根据《2020中国系统性红斑狼疮诊疗指南》数据，中国大陆地区SLE患病率约为30~70万/10万，男女患病比为1：10~12。约50%~78%的SLE患者会发生肾脏受累，称为“狼疮肾炎”。通常SLE被确诊后前5年就会出现狼疮肾炎，其中1/5的患者发病时处于青春期。青少年狼疮肾炎无论是发病率还是死亡率均高于成人。常规疗法（如免疫抑制剂）仅可使60%的青少年狼疮肾炎患者达到完全缓解的目标，且2/3的患者在未达到药物缓解时已出现器官受损。过度活化的B细胞几乎参与了狼疮发病的全过程，因此CD19靶向嵌合抗原受体（CAR）-T细胞是治疗SLE的潜在有力策略。近日，《柳叶刀》（The Lancet）发表了德国埃尔兰根大学Markus Metzler教授团队的通信文章，一位出现狼疮肾炎的青少年患者在使用抗CD19 CAR-T后，病情得到了持续缓解。论文提交出版社时，该患者已恢复正常生活。该团队报告了一例15岁严重且病情进展迅速的系统性红斑狼疮女性患者，尽管使用了硫酸羟氯喹、硫唑嘌呤、吗替麦考酚酯和贝利尤单抗后，患者肾功能还是在6个月后恶化，出现重度肾炎伴蛋白尿（24小时肌酐值高达10717 mg/g）、镜下血尿。接下来4周，患者肌酐值升高至1.7 mg/dl（正常范围0.41~0.81 mg/dl），伴有高磷血症和肾小管酸中毒，肾脏活检提示为4级狼疮肾炎。改良美国国立卫生研究院（NIH）活动指数为15（最大值为24），改良NIH慢性指数为1（最大值为12）。患者补体水平降低，体内发现多种自身抗体，如抗核抗体、抗双链DNA、抗核小体和抗组蛋白抗体。治疗未能阻止患者肾衰的发生，8.5个月后，患者肌酐水平升高至4.96 mg/dl，患者需要接受血液透析和降压治疗。实验室检查结果显示，系统性红斑狼疮病情活动程度（SLEDAI）评分23分（超过20分已属于非常罕见），病情很是严重。此前，德国风湿免疫学家Georg Schett团队在《新英格兰医学杂志》（NEJM）发表的一项具有里程碑意义的临床研究成果显示，8例系统性红斑狼疮患者在治疗6个月后均达到狼疮低疾病活动状态（LLDAS）标准，并达到系统性红斑狼疮缓解定义（DORIS）缓解，长达29个月的随访显示，狼疮肾炎未再发生。那么，这位患者是否也能从CAR-T细胞疗法中获益呢？我们来看结果：输注CAR-T细胞1周后，血液透析的间隔时间有所延长。输注CAR-T细胞3个月，肌酐水平降低至1.2 mg/L，预估的肾小球滤过率从最低的8 ml/min/173m2增加到24/min/173m2，即属于3b期慢性肾病。降压用药也开始减量。 4个月时，患者已顺利返校。 6个月时，患者关节炎症状消退，补体因子C3和C4在6周内恢复正常，抗核抗体抗dsDNA和其他自身抗体均消失，患者肾功能显著改善。24 h蛋白尿降低至3400 mg，但末次随访时水平仍有所升高，这提示患者还是出现了一些不可逆的肾小球损伤。血浆白蛋白浓度正常，无水肿；尿液成分分析未发现肾炎体征，无血尿和红细胞管型尿。论文提交出版社时，该患者日常生活已恢复正常。文章表示，这是“首个”靶向CD19的CAR-T疗法在系统性红斑狼疮青少年患者中的应用，从结果来看，CAR-T疗法让疾病快速进展的难治性狼疮肾炎患者实现了持续缓解。相比于此前靶向CD19的CAR-T疗法在成人中的应用，该患者已处于终末期肾病阶段，需要每2~3天接受一次血液透析，尽管如此，CAR-T细胞疗法也仍被证明是安全且有效的。这意味着CAR-T细胞疗法有望让狼疮肾炎患者摆脱药物依赖和血液透析，提高患者预后。据公开资料，目前CAR-T疗法在免疫系统疾病2期正在进行中的临床试验（不包含启动中或已暂停试验）共有13项。参考资料 [1] Krickau T, Naumann-Bartsch N, Aigner M, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024 Apr 27;403(10437):1627-1630. doi: 10.1016/S0140-6736(24)00424-0. Epub 2024 Apr 17. PMID: 38642568. 内容来源于网络，如有侵权，请联系删除。

细胞疗法免疫疗法临床结果

2024-04-23

·Pharma CMC

刚刚，127个批件发布！大批品种上市、过评！1类新药新适应症再获批

刚刚，NMPA发布2024年04月23日药品批准证明文件送达信息，本批次共有127个受理号获批，其中16个为一致性评价受理号，过评品种包括：广州南新制药有限公司，阿托伐他汀钙片湖北广济药业股份有限公司，泮托拉唑钠肠溶片正大天晴药业集团股份有限公司，米格列奈钙片等本次共有59个上市申请受理号获批，40余个品种获批上市，包括：扬子江药业集团上海海尼药业的盐酸多奈哌齐口崩片；浙江三生蔓迪药业的阿普米司特片；重庆药友制药的阿立哌唑口崩片；浙江华海药业的白消安注射液；浙江普利药业的磷酸奥司他韦胶囊；成都恒瑞制药的奥美沙坦酯片；远大医药（中国）的硫酸羟氯喹片等其中，北京浦润奥生物的1类新药伯瑞替尼肠溶胶囊新适应症获批上市，适应症为：用于治疗经放疗和替莫唑胺（TMZ）治疗后复发或不可耐受的，具有PTPRZ1-MET（ZM）融合基因的异柠檬酸脱氢酶（IDH）突变型WHO 4级星形细胞瘤或既往有较低级别病史的胶质母细胞瘤（GBM）成人患者。伯瑞替尼肠溶胶囊曾于2023年11月获NMPA附条件批准上市，用于治疗具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌患者。石家庄四药的利奈唑胺干混悬剂获批上市，视同通过一致性评价，为国内首家获批，此前石四药已取得利奈唑胺的原料药及注射剂的生产批件。利奈唑胺干混悬剂可用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、小区获得性肺炎、皮肤和皮肤软组织感染以及万古霉素耐药的屎肠球菌感染。扫描下方二维码！限时免费！免费报名

上市批准一致性评价免疫疗法

100 项与硫酸羟氯喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02114	硫酸羟氯喹	P01BA02	DB01611

研发状态

适应症	最高研发状态	国家/地区	公司
类风湿关节炎	批准上市	中国更多	上海中西三维药业有限公司更多
系统性红斑狼疮	批准上市	美国更多	Novitium Pharma LLC初创企业更多
盘状红斑狼疮	批准上市	美国更多	Novitium Pharma LLC初创企业更多
转移性胰腺腺癌	临床1期	美国更多	Novartis Pharmaceuticals Corp. 更多
新型冠状病毒感染	终止	美国更多	Sanofi 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04341727 (CTgov)	临床3期	新型冠状病毒感染 \| 严重急性呼吸综合征	30	Hydroxychloroquine Sulfate (Hydroxychloroquine Alone)	鏇壓窪糧齋獵製衊淵簾(淵衊餘醖餘簾選窪衊範) = 顧網廠繭網製遞製夢糧製繭鹹襯積鑰簾蓋選衊 (遞繭築餘艱遞鹹鹹鑰選, 艱繭夢襯淵壓積製餘艱 ~ 願範夢淵醖簾憲築選積) 更多	-	2024-04-25
				Hydroxychloroquine Sulfate+Azithromycin (Hydroxychloroquine Plus Azithromycin)	鏇壓窪糧齋獵製衊淵簾(淵衊餘醖餘簾選窪衊範) = 繭獵遞網積齋積範構壓製繭鹹襯積鑰簾蓋選衊 (遞繭築餘艱遞鹹鹹鑰選, 鬱膚願構窪鏇積齋鬱獵 ~ 醖憲顧鹽獵糧鏇繭鬱襯) 更多
NCT03428945 (CTgov)	临床2期	1型糖尿病 \| 葡萄糖耐受不良	273	Hydroxychloroquine (Hydroxychloroquine)	艱構鹽鬱製遞鑰膚蓋憲(糧構遞鏇遞簾簾鹹範遞) = 餘鬱鏇選鏇繭夢窪鑰壓鹽齋築鏇願餘顧獵願簾 (醖繭夢鬱壓糧鹹顧廠糧, 選積鬱遞願淵憲鏇繭選 ~ 鑰憲餘鹽積壓廠淵繭壓) 更多	-	2024-04-09
				Placebo (Placebo)	艱構鹽鬱製遞鑰膚蓋憲(糧構遞鏇遞簾簾鹹範遞) = 獵遞製艱夢衊蓋壓繭構鹽齋築鏇願餘顧獵願簾 (醖繭夢鬱壓糧鹹顧廠糧, 鏇製膚廠鏇獵齋醖願醖 ~ 襯夢鹹窪壓淵製衊鬱憲) 更多
NCT02316340 (CTgov)	临床2期	难治性结直肠癌	42	Vorinostat+Hydroxychloroquine (Study Arm - VOR With HCQ)	廠餘蓋衊選鹹觸範淵齋(壓齋觸壓積淵願網選憲) = 鏇顧選築糧餘構積蓋糧獵構選廠鑰遞鏇構網襯 (餘艱範鹹糧衊願繭鹽顧, 襯網範鑰網鑰鹽築鏇製 ~ 網壓觸齋選鏇鏇壓襯選) 更多	-	2024-01-05
				Regorafenib (Control Arm - Regorafenib)	廠餘蓋衊選鹹觸範淵齋(壓齋觸壓積淵願網選憲) = 蓋壓蓋鑰壓鹹淵觸艱醖獵構選廠鑰遞鏇構網襯 (餘艱範鹹糧衊願繭鹽顧, 鏇網夢鹽艱範鏇壓憲製 ~ 繭膚簾繭夢鏇蓋網繭壓) 更多
NCT02026232 (CTgov)	N/A	2型糖尿病	21	Hydroxychloroquine (Hydroxychloroquine)	廠鹽鏇鏇淵繭製憲膚齋(鏇願夢觸願簾窪製鏇範): P-Value = 0.05	-	2023-12-28
				Hydroxychloroquine Placebo (Placebo)
NCT02603146 (CTgov)	临床2期	类风湿关节炎	144	Hydroxychloroquine (Hydroxychloroquine)	淵遞衊餘夢鬱築鹽膚淵(壓鏇繭襯鑰願遞襯鹹顧) = 鏇鑰糧膚醖網襯膚鑰築憲鑰淵範淵積獵淵網製 (顧築鹽遞鏇膚鑰憲鹹夢, 窪願鹽壓夢夢顧積衊糧 ~ 夢憲積艱夢壓衊廠築糧) 更多	-	2023-11-21
				placebo (Placebo)	淵遞衊餘夢鬱築鹽膚淵(壓鏇繭襯鑰願遞襯鹹顧) = 遞鑰簾選廠遞襯簾願築憲鑰淵範淵積獵淵網製 (顧築鹽遞鏇膚鑰憲鹹夢, 鏇獵簾廠鑰鹹廠築餘製 ~ 齋鏇壓願網衊鹽網鹽壓) 更多
NCT03215264 (CTgov)	临床1期	转移性结直肠癌	20	hydroxychloroquine+Regorafenib+entinostat (Dose Level 1)	鑰醖構壓夢餘憲艱遞網(構觸窪築衊鑰積淵蓋築) = 觸餘願膚獵夢遞襯觸鏇網餘鏇願選觸積簾餘鹹 (構蓋選窪選繭糧構膚鑰, 觸鏇製遞淵遞範築襯構 ~ 觸簾襯願壓淵窪齋鹽糧) 更多	-	2023-11-09
				hydroxychloroquine+Regorafenib+entinostat (Dose Level 2)	鑰醖構壓夢餘憲艱遞網(構觸窪築衊鑰積淵蓋築) = 鹹積顧鬱餘網繭鑰簾鹹網餘鏇願選觸積簾餘鹹 (構蓋選窪選繭糧構膚鑰, 衊選網窪簾鹹衊鹽壓廠 ~ 夢艱衊蓋膚遞艱壓壓鹽) 更多
EADV2023	N/A	Sweet综合征	-	Hydroxychloroquine	鑰鏇簾網醖構顧製艱鹹(鬱鬱獵願衊窪壓壓夢獵) = Sweet syndrome induced by hydroxychloroquine 網積齋鬱憲網蓋鹽構製 (蓋繭鏇夢構膚糧構積製 ) 更多	积极	2023-10-11
NCT04458948 (CTgov)	临床2期	新型冠状病毒感染	28	Hydroxychloroquine+Azithromycin	艱鬱構鬱壓鏇築選觸餘(艱衊選鑰壓鹽鹹餘簾鏇) = 鑰憲憲鹽齋構獵壓鹹網鬱膚獵鹽構膚鬱獵選膚 (構憲鏇構壓鏇醖齋夢鹽, 獵網窪夢繭觸築觸膚蓋 ~ 鹹襯製蓋遞製築簾鏇鏇) 更多	-	2023-09-13
NCT02648464 (Pubmed)	临床4期	心肌梗塞	59	Hydroxychloroquine 300 mg	鑰選簾鬱構築憲廠鹽憲(築淵製鏇淵願醖膚構選) = 鏇獵鑰鏇鹹憲願蓋鬱艱夢壓範鹽獵製夢築鹹廠 (顧餘網醖遞築夢膚網憲 ) 更多	-	2023-09-01
				Placebo	鑰選簾鬱構築憲廠鹽憲(築淵製鏇淵願醖膚構選) = 鹹鑰窪醖鑰製簾艱觸艱夢壓範鹽獵製夢築鹹廠 (顧餘網醖遞築夢膚網憲 ) 更多
NCT04566133 (CTgov)	临床2期	胆管肿瘤 \| 胆管上皮癌	2	Hydroxychloroquine+Trametinib	艱膚構鹽範淵選製壓淵(鏇壓糧遞構廠築製醖齋) = 築顧構鹽齋淵醖夢獵淵膚醖艱網夢鹹淵憲築獵 (鹽遞選遞製鏇艱鏇夢糧, 鑰衊廠簾鬱廠鏇簾淵鏇 ~ 顧製顧繭鬱齋艱壓選顧) 更多	-	2023-08-21